Keyphrases
Systematic Meta-analysis
90%
Meta-analysis
90%
Gynecological Cancer
90%
Combination Therapy
63%
Objective Response Rate
55%
Targeted Therapy
54%
Absorbance
45%
Phenylalanine
45%
Ligand Binding
45%
Protein Structure
45%
Differential Scanning Fluorimetry
45%
Tryptophan
45%
Breast Cancer Cells
45%
Bonding Stability
45%
Adoptive Cell Therapy
45%
Product Characterization
45%
Product Characteristics
45%
Messenger RNA Vaccine
45%
UV Absorption
45%
Protein-ligand Interaction
45%
Cancer Therapy
45%
Cluster of Differentiation 47 (CD47)
45%
Disulfide Bond
45%
Phlebotomus Papatasi
45%
PpSP15
45%
Threonine Phosphorylation
45%
Genomic Landscape
45%
Tyrosine
45%
Phosphorylation
45%
Clinical Data
45%
Vaccine Antigen
45%
Plantlet Regeneration
45%
Threonine
45%
Absorbance Maxima
45%
Kappaphycus Alvarezii
45%
UV Light
45%
Beta-blockers
45%
KRAS mutation
45%
Receiving Phase
45%
Anti-CD47 Monoclonal Antibody
36%
KRASG12C Inhibitors
30%
Scaffold Protein
30%
Immunogenicity
29%
Overall Survival
25%
Solid Tumors
24%
Clinical Trials
24%
Traditional Vaccines
22%
Vaccine Development
22%
Host Cell
22%
Biophysical Assays
22%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
100%
Overall Survival
81%
Diseases
78%
Carcinogenesis
75%
Clinical Trial
65%
Combination Therapy
63%
Preclinical Study
45%
Connective Tissue Cancer
45%
Receptor
45%
Chagas Disease
45%
Female Genital Tract Cancer
45%
Severe Acute Respiratory Syndrome Vaccine
45%
Severe Acute Respiratory Syndrome
45%
Multiple Cancer
45%
Immune Deficiency
45%
Recombinant Receptor
45%
Therapeutic Vaccine
45%
Uterine Cervix Cancer
45%
Disease Course
45%
Trypanosoma cruzi
45%
Monoclonal Antibody
45%
Progression Free Survival
36%
Recombinant Protein
30%
Good Manufacturing Practice
30%
Adverse Event
27%
Antibody
22%
Aluminum Hydroxide
22%
SARS Coronavirus
22%
Neutralizing Antibody
22%
Respiratory Tract Infection
22%
Pandemic
22%
Anemia
18%
Prevalence
18%
Bone Metastasis
18%
Solid Malignant Neoplasm
18%
Headache
18%
Chemotherapy
16%
Mitogen Activated Protein Kinase
15%
Drug Development
15%
Epidermal Growth Factor Receptor
15%
Tolerability
15%
Endometriosis
9%
Biological Marker
9%
Nausea
9%
Phase I Trials
9%
Squamous Cell Carcinoma
9%
Immunotherapy
9%
Mixed Model
9%
Chill
9%
Medicine and Dentistry
Neoplasm
100%
Female Genital Tract Cancer
90%
Overall Survival
81%
Targeted Therapy
72%
Cell Therapy
63%
T Cell
58%
Diseases
58%
Hazard Ratio
54%
extracellular signal regulated kinase
54%
T Lymphocyte Receptor
51%
Cancer Immunotherapy
45%
Disease Course
45%
Meta-Analysis
45%
Carcinogenesis
45%
Cell Cycle
45%
Experimental Therapy
45%
Cervical Cancer
45%
Immune Deficiency
45%
Systematic Review
45%
Proteus Syndrome
45%
Molecularly Targeted Therapy
45%
Progression Free Survival
36%
Immunocompetent Cell
27%
Tumor Antigen
27%
Chimeric Antigen Receptor T-Cell
24%
Solid Malignant Neoplasm
24%
Tumor Infiltrating Lymphocyte
19%
Cancer
18%
Bone Metastasis
18%
Clinical Trial
18%
Lymphocyte
18%
Immunity
18%
Prevalence
18%
Adverse Event
15%
Cancer Types
15%
Cytokine
9%
Antigen Presentation
9%
Programmed Death-Ligand 1
9%
Hematologic Malignancy
9%
Membrane Antigen
9%
Biological Marker
9%
Distant Metastasis
9%
Absolute Neutrophil Count
9%
T Cell Receptor
9%
Cell Expansion
9%
Mediator
9%
Kaplan Meier Method
9%
Immunotherapy
9%
Proportional Hazards Model
9%
Phase I Trials
9%